Clinical Trials Sponsored by Shanghai De Novo Pharmatech Co., Ltd.

Total 10 results

Shanghai De Novo Pharmatech Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Shanghai De Novo Pharmatech Co., Ltd.

Unknown

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

Advanced Solid Tumors

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 (WX-081)

Pulmonary Tuberculosis

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Gastric Type Adenocarcinoma (GAS) With STK11 Mutation

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Jiatan Pharmatech Co., Ltd

Enrolling by invitation

Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients (WISH)

Rifampicin-resistant Tuberculosis

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

PIK3CA Mutation-Related Tumors

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

Advanced Cancer

China

Clinical Trials Sponsored by Shanghai De Novo Pharmatech Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations